Drugs / Lactobacillus acidophilus
Lactobacillus acidophilus
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06793514 | Feb → May 2025 overdue | dry eye syndrome | Mohsen Pourazizi | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT01370551 | Apr 2011 → Jul 2012 | postmenopausal atrophic vaginitis | Medinova AG | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 25 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05539287 | Sep 2022 → Aug 2024 | epilepsy | Tanta University | Completed | Met primary |
| Phase 2 | NCT03033199 | Jan 2017 → Feb 2018 | autoimmune thrombocytopenia | Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT02535962 | Oct 2016 → Sep 2017 | aphthous stomatitis, cervical lymphadenitis, periodic fever syndrome, pharyngitis | Connecticut Children's Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02307383 | Oct 2014 → Oct 2015 | — | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 2 | NCT00268164 | Jun 2004 → Mar 2007 | ulcerative colitis | Hvidovre University Hospital | Terminated | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT01358708 | Jun 2010 → Sep 2011 | irritable bowel syndrome | Forest Laboratories | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01558388 | Sep 2009 → Dec 2012 | bacterial vaginosis | University of Brescia | Unknown | No outcome recorded |
| Phase not applicable3 trials · 1 missed | ||||||
| — | NCT04706559 | Jan → Sep 2021 | atopic eczema | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| — | NCT04701775 | Sep 2018 → Feb 2019 | hyperlipidemia | Eastern Mediterranean University | Completed | No outcome recorded |
| — | NCT00835874 | Jun 2007 → Jul 2009 | infectious disease with sepsis, necrotizing enterocolitis | Tel-Aviv Sourasky Medical Center | Terminated | Missed primary Stop: Enrollment |
| Comparator or background therapy9 trials | ||||||
| Phase 1/2 | NCT00746226 Comparator | Mar → Jun 2006 | seasonal allergic rhinitis | Danisco | Completed | No outcome recorded |
| Phase 2 | NCT07293910 Comparator | Feb → Dec 2026 expected | Helicobacter pylori infectious disease | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT07296146 Comparator | Dec 2025 → Mar 2026 overdue | anemia, chronic kidney disease | Badr University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01340469 Comparator | Jan 2005 → Mar 2008 | necrotizing enterocolitis, nosocomial infection | King Chulalongkorn Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07758335 Comparator | Jul 2025 → Mar 2027 expected | ulcerative colitis | National Hepatology & Tropical Medicine Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT07144475 Comparator | Jan → Nov 2024 | colorectal cancer | Dharmais National Cancer Center Hospital | Completed | No outcome recorded |
| — | NCT05674864 Comparator | Jan → Aug 2023 | Helicobacter pylori infectious disease | Tanta University | Unknown | No outcome recorded |
| — | NCT00256022 Comparator | Jul → Dec 2007 | — | Melbourne Health | Withdrawn | No outcome recorded |
| — | NCT00256087 Comparator | Jan 2005 → Jan 2010 | — | Melbourne Health | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-03-14 | Cell Biotech Co., Ltd. | Regulatory Portfolio of Probiotic Ingredients from Cell Biotech Co. Ltd. achieves GRAS “No Objection” from U.S. FDA cellbiotech.com ↗
Portfolio of Probiotic Ingredients from Cell Biotech Co. Ltd. achieves GRAS “No Objection” from U.S. FDA |
| 2017-02-27 | Winclove Probiotics B.V. | Results Probiotic supplements beneficially affect Tryptophan–Kynurenine Metabolism wincloveprobiotics.com ↗
The ratio of subjects taking the placebo who experienced one or more URTI symptoms was increased 2.2-fold compared to those on probiotics (PLA 0.79, PRO 0.35; p = 0.02). |
| 2016-08-31 | Winclove Probiotics B.V. | Results New study: probiotics and allergic rhinitis wincloveprobiotics.com ↗
In a recently finished study the formulation showed to singificantly improve quality of life in patients with allergic rhinitis. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-14 | Pendulum Therapeutics | Best Probiotic for Gut Health pendulumlife.com ↗ |
| 2025-07-11 | Pendulum Therapeutics | What Is the Best Probiotic for Women? pendulumlife.com ↗ |
| 2024-03-14 | Cell Biotech Co., Ltd. | Portfolio of Probiotic Ingredients from Cell Biotech Co. Ltd. achieves GRAS “No Objection” from U.S. FDA cellbiotech.com ↗ |
| 2017-02-27 | Winclove Probiotics B.V. | Probiotic supplements beneficially affect Tryptophan–Kynurenine Metabolism wincloveprobiotics.com ↗ |
| 2016-08-31 | Winclove Probiotics B.V. | New study: probiotics and allergic rhinitis wincloveprobiotics.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus acidophilus | “The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium...” NCT06793514 ↗19“probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one...” NCT03033199 ↗ “Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.” NCT01340469 ↗ “Mothers were assigned to supplementation with Lactobacillus acidophilus and Bifidobacteria lactis 2 × 10(E) [DOSAGE ERROR CORRECTED] CFU/d or to placebo” PMID 23934538 ↗ Aug 2013 “The second active treatment group will receive enteral feeding (with fibre) plus the probiotic Lactobacillus acidophilus included in the feeding regime.” NCT00256087 ↗ “Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days.” NCT02307383 ↗ “Two different lactobacillus strains will be assessed in the study: Lactobacillus Acidophilus and Lactobacillus Fermentum.” NCT00256022 ↗ “same antiepileptic regimen plus a daily probiotic (Lactobacillus acidophilus) supplement.” PMID 41693686 ↗ Mar 2026 “Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis (BB12)” NCT00268164 ↗ “Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets” PMID 24718774 ↗ Apr 2014 “EPO (4000 IU) + Probiotic (Lactobacillus acidophilus, 5 billion)” NCT07296146 ↗ |
| Known as | Acidophilus | “Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,” NCT02696512 ↗ |
| Known as | Bacillus acidophilus whole | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109070 ↗ |
| Known as | Bacterium acidophilum whole | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109070 ↗ |
| Known as | Gynatren | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109070 ↗ |
| Known as | La-5 | “A randomised double-blind placebo-controlled trial with Lactobacillus
acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for
maintenance of remission in...” PMID 21453880 ↗ Jan 20111“Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis (BB12)” NCT00268164 ↗ |
| Known as | Lacteol | “Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.” NCT01358708 ↗ |
| Known as | Lactobacillus acidophilus component of lactinex | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109070 ↗ |
| Known as | Lactobacillus acidophilus whole | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109070 ↗ |
| Known as | Lactobacterium acidophilum whole | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109070 ↗ |
| Known as | Probiotic | “EPO (4000 IU) + Probiotic (Lactobacillus acidophilus, 5 billion)” NCT07296146 ↗ |
| Known as | Thermobacterium intestinale whole | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109070 ↗ |
| Action | Inhibit | “Probiotics (primarily Lactobacillus and Bifidobacterium strains) enhance eradication rates by restricting bacterial growth” NCT07293910 ↗ |
| Modality | Other / unclassified | “pre-operative prophylactic probiotic Lactobacilli tablets” NCT00256022 ↗ |
| Route | Other | “Two capsules containing Lactobacillus acidophilus (2x10 9 organisms per capsule) will be delivered via the feeding tube 12 hourly.” NCT00256087 ↗ |